A new study done by scientists in Switzerland and Sweden investigated the use of automated systems to develop multispecific antibodies.

The concept of using proteins and other secreted factors to treat heart attack, rather than replacement cells, has emerged.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...

This protocol refines co-immunoprecipitation (co-IP) for lipid droplet (LD)-specific protein interactions by isolating ...